These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18360705)

  • 1. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
    Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
    Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
    Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
    Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V; Haas C; Bonifer R; Ertel C
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with virus-modified tumor cells.
    Schirrmacher V; Ahlert T; Pröbstle T; Steiner HH; Herold-Mende C; Gerhards R; Hagmüller E; Steiner HH
    Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
    Blanco B; Holliger P; Alvarez-Vallina L
    Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Int J Cancer; 2006 Feb; 118(3):658-67. PubMed ID: 16108015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells.
    Song LP; Cheng JL; Wang XB; Zhang Z; Fang M; Zhou ZY; Huang HL
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jun; 35(6):503-10. PubMed ID: 12796809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
    Janke M; Peeters B; Zhao H; de Leeuw O; Moorman R; Arnold A; Ziouta Y; Fournier P; Schirrmacher V
    Int J Oncol; 2008 Oct; 33(4):823-32. PubMed ID: 18813797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological effects of BCG as an adjuvant in autologous tumor vaccines.
    Li Q; Normolle DP; Sayre DM; Zeng X; Sun R; Jiang G; Redman BD; Chang AE
    Clin Immunol; 2000 Jan; 94(1):64-72. PubMed ID: 10607491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.
    Schirrmacher V; Haas C; Bonifer R; Ahlert T; Gerhards R; Ertel C
    Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
    Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
    J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
    Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing.
    Grosse-Hovest L; Hartlapp I; Marwan W; Brem G; Rammensee HG; Jung G
    Eur J Immunol; 2003 May; 33(5):1334-40. PubMed ID: 12731059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.
    Bian H; Fournier P; Moormann R; Peeters B; Schirrmacher V
    Int J Oncol; 2005 Feb; 26(2):431-9. PubMed ID: 15645128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.